SXTP60 DEGREES PHARMACEUTICALS,...

Nasdaq 60degreespharma.com


$ 1.30 $ -0.06 (-4.41 %)    

Monday, 09-Sep-2024 15:59:27 EDT
QQQ $ 455.25 $ 5.77 (1.29 %)
DIA $ 409.08 $ 4.58 (1.13 %)
SPY $ 546.60 $ 6.05 (1.12 %)
TLT $ 99.96 $ 0.43 (0.43 %)
GLD $ 231.58 $ 0.97 (0.42 %)
$ 1.3
$ 1.30
$ 1.29 x 100
-- x --
$ 1.30 - $ 1.30
$ 1.03 - $ 18.36
96,713
na
2.3M
$ 0.90
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 08-14-2024 06-30-2024 10-Q
2 05-15-2024 03-31-2024 10-Q
3 04-01-2024 12-31-2023 10-K
4 11-20-2023 09-30-2023 10-Q
5 08-25-2023 06-30-2023 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 60-degrees-pharmaceuticals-announces-4m-private-placement-for-the-issuance-and-sale-of-2898551-shares-of-its-common-stock-series-a-warrants-to-purchase-up-to-2898551-shares-of-common-stock-and-short-term-series-b-warrants-to-purchase-up-to-2898551-shares-of-common-stock-at-a-purchase-price-of-138-per-share

60 Degrees Pharmaceuticals, Inc. (NASDAQ:SXTP, SXTPW)))) ("60P" or the "Company"), a pharmaceutical company foc...

 hc-wainwright--co-reiterates-neutral-on-60-degrees

HC Wainwright & Co. analyst Edward White reiterates 60 Degrees (NASDAQ:SXTP) with a Neutral.

 60-degrees-q2-eps-423-up-from-1684-yoy-sales-12497k-up-from-5953k-yoy

60 Degrees (NASDAQ:SXTP) reported quarterly losses of $(4.23) per share. This is a 74.88 percent increase over losses of $(16.8...

 60-degrees-pharmaceuticals-announces-1-for-12-reverse-stock-split-effective-august-12-2024

Aims To Comply With Nasdaq $1.00 Minimum Bid Price Requirement; Trading To Continue Under Symbol "SXTP" With New CUSIP ...

 why-are-60-degrees-pharmaceuticals-shares-up-by-50-today

60 Degrees Pharmaceuticals Inc. (NASDAQ: SXTP) shares are surging on Friday following the company's announcement of clinica...

 60-degrees-pharmaceuticals-signs-clinical-trial-agreements-with-three-planned-trial-sites-for-tafenoquine-babesiosis-study

The Tafenoquine for Babesiosis clinical trial will be conducted at three sites: Yale University, Rhode Island Hospital and Tuft...

 reported-earlier-60-degrees-pharma-announces-irb-approval-of-clinical-study-of-tafenoquine-for-treatment-of-babesiosis-in-immunocompromised-patients-with-persistent-babesia-microti-despite-prior-treatment

60 Degrees Pharmaceuticals, Inc. (NASDAQ:SXTP, SXTPW)))) ("60 Degrees Pharmaceuticals" or the "Company"), a pha...

 60-degrees-pharmaceuticals-enrolls-first-patient-in-clinical-trial-for-tafenoquine-to-treat-babesiosis-at-tufts-medical-center

The efficacy and safety of tafenoquine in treating human babesiosis will be evaluated in a randomized, double-blind, placebo-co...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION